M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma
Authors:
Top Cited Papers
Open Access
- 23 July 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 81 (18) , 4778-4793
Abstract
N6-methyladenosine (m6A) has been reported as an important mechanism of posttranscriptional regulation. Programmed death-ligand 1 (PD-L1) is a primary immune inhibitory molecule expressed on tumor cells that promotes immune evasion. Here we report ALKBH5 as an important m6A demethylase that orchestrates PD-L1 expression in intrahepatic cholangiocarcinoma (ICC). Regulation of PD-L1 expression by ALKBH5 was confirmed in human ICC cell lines. Sequencing of the m6A methylome identified PD-L1 mRNA as a direct target of m6A modification whose levels were regulated by ALKBH5. Furthermore, ALKBH5 and PD-L1 mRNA were shown to interact. ALKBH5 deficiency enriched m6A modification in the 3′UTR region of PD-L1 mRNA, thereby promoting its degradation in a YTHDF2-dependent manner. In vitro and in vivo, tumor-intrinsic ALKBH5 inhibited the expansion and cytotoxicity of T cells by sustaining tumor cell PD-L1 expression. The ALKBH5-PD-L1–regulating axis was further confirmed in human ICC specimens. Single-cell mass cytometry analysis unveiled a complex role of ALKBH5 in the tumor immune microenvironment by promoting the expression of PD-L1 on monocytes/macrophages and decreasing the infiltration of myeloid-derived suppressor-like cells. Analysis of specimens from patients receiving anti-PD1 immunotherapy suggested that tumors with strong nuclear expression patterns of ALKBH5 are more sensitive to anti-PD1 immunotherapy. Collectively, these results describe a new regulatory mechanism of PD-L1 by mRNA epigenetic modification by ALKBH5 and the potential role of ALKBH5 in immunotherapy response, which might provide insights for cancer immunotherapies. Significance: This study identifies PD-L1 mRNA as a target of ALKBH5 and reveals a role for ALKBH5 in regulating the tumor immune microenvironment and immunotherapy efficacy.Keywords
All Related Versions
Funding Information
- National Research Program of China (2017YFA0505803, 2017YFC0908100)
- Infectious Diseases (2018ZX10732202–001, 2018ZX10302207–004)
- National Natural Science Foundation of China (81790633, 81830054, 81902412, 81672860, 61922047, 82002921, 81802853)
- National Natural Science Foundation of Shanghai (17ZR143800)
- Youth Foundation of Fudan University Shanghai Cancer Center (YJQN201934)
This publication has 39 references indexed in Scilit:
- PD-1 BlockersCell, 2015
- m6A RNA Modification Controls Cell Fate Transition in Mammalian Embryonic Stem CellsCell Stem Cell, 2014
- CholangiocarcinomaThe Lancet, 2014
- N6-methyladenosine-dependent regulation of messenger RNA stabilityNature, 2013
- RNA-Methylation-Dependent RNA Processing Controls the Speed of the Circadian ClockCell, 2013
- Myeloid-cell differentiation redefined in cancerNature Immunology, 2013
- ALKBH5 Is a Mammalian RNA Demethylase that Impacts RNA Metabolism and Mouse FertilityMolecular Cell, 2013
- Topology of the human and mouse m6A RNA methylomes revealed by m6A-seqNature, 2012
- Interferon regulatory factor‐1 is prerequisite to the constitutive expression and IFN‐γ‐induced upregulation of B7‐H1 (CD274)FEBS Letters, 2006
- Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunityNature Reviews Immunology, 2004